ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
OneSource reported strong Q1 FY27 results with Revenue of INR 4,490M (up 37% YoY) and EBITDA of INR 1,233M (up 39% YoY), driven by semaglutide commercialization and biologics expansion.
Management is aggressively optimistic, leveraging the GLP-1 (Semaglutide) boom to mask temporary supply disruptions. Strategic shift toward CDMO for Softgel and Biologics aims to diversify beyond traditional captive manufacturing.
Q4 FY26 marked a strong recovery with 47% sequential revenue growth to US$48M, driven by Semaglutide launches and drug-device combinations.
Onesource Q4 FY26 shows strong sequential recovery driven by semaglutide drug-device combination launches, although annual profits were dragged down by prior delays and exceptional items.